Study Comparing Lazertinib with Subcutaneous and Intravenous Amivantamab for EGFR-Mutated Advanced Lung Cancer

Inclusion Criteria

• Have advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations (Exon 19 deletion or Exon 21 L858R mutation) confirmed by a certified lab test.
• Have previously been treated with osimertinib (or another similar drug) and platinum-based chemotherapy.
• Have at least one tumor that can be measured by scans.
• Be in good overall health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Any side effects from previous cancer treatments must have improved to a mild level or returned to baseline, except for hair loss, mild nerve damage, and mild hypothyroidism that is stable with medication.

Exclusion Criteria

• Have received more than one round of platinum-based chemotherapy and EGFR inhibitors.
• Have had radiation therapy for symptom relief less than 7 days before starting the study.
• Have worsening or symptomatic brain metastases.
• Have cancer that has spread to the membranes around the brain or spinal cord that hasn't been treated.
• Have uncontrolled pain related to the tumor.
• Have a history of lung diseases like interstitial lung disease or radiation-induced lung inflammation.